Background: Uveitis in children is rare. Intensive interactions between ophthalmologists and paediatric rheumatologists are needed in order to choose the best therapeutic strategies for severe uveitis attacks. Objectives: Describe a cohort of 74 patients with paediatric uveitis. Methods: Retrospective analysis of children followed for uveitis before 18, by one paediatric rheumatologist (SGC) for systemic treatments' management and members of 3 ophthalmologic departments specialized in uveitis care in children (AR, CT, ML and BB) in Paris, during the 2006-16 period. Results: There were 74 paediatric uveitis, 42 anterior (57%, group1), 16 intermediate (21%, gr2), 7 posterior (9%, gr3) and 9 pan-uveitis (12%, gr4). Gender was equal in gr2-4, but there were more females in gr1. At presentation, mean ages were 8.6±4.1, 9.8±3.9, 9.1±3.6 and 10±4.2 years old. Mean follow-up was 3.7±3.7 years. JIA was the leading cause of gr1 uveitis (45%); gr2-3 uveitis were idiopathic in 81% and 86%, respectively. In gr4, etiologies were found in 7 out of 9 patients (Behçet-3, JIA-2, BBS-1, TINU-1). Conclusions: Paediatric uveitis induce a very high-level burden in children, even when anterior and sometimes despite optimal therapeutic management in tertiary care centers. Their early recognition and tight control in specialized units are absolutely required in order to decrease the level of definitive complications.
Background: Identifying predictors for early clinically inactive disease (CID) would allow stratified treatment decisions at diagnosis, minimising the burden of unnecessary therapies. JIA core outcome variables (COVs) are routinely collected and would therefore be convenient predictors. However, different groups of children are identified by current CID definitions (Wallace's preliminary criteria vs. clinical Juvenile Arthritis Disease Activity Score in 10 joints (cJADAS10)) and predictors may differ depending on which CID outcome is applied. Objectives: To assess whether baseline COVs predict achievement of CID according to Wallace's preliminary criteria or the cJADAS10 cut-off in patients with JIA. Methods: Children and young people enrolled to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort, before January 2011, were selected if diagnosed with oligoarticular, RF-negative or RF-positive polyarticular JIA. At one year following initial presentation to paediatric rheumatology, children Abstract THU0532 - Results: A total of 238 IV ABA-treated pts were identified with 89 pts having ≥12M of ABA treatment. The mean (SD) follow-up duration was 1.73 (1.28) yrs for the total IV ABA cohort and 2.28 (1.03) yrs for the ≥12-M subgroup. Most pts were female, and mean age was 12.4 yrs. Overall, the total IV ABA cohort was more likely to have a claim in the BL period for asthma and cardiovascular disease versus the ≥12-M subgroup; the ≥12-M subgroup was more likely to have uveitis (Table) . The most frequent other bDMARD claim for the total IV ABA-treated pts in the biologic holiday group was etanercept (41.9%), and adalimumab for
